Rubiadin-1-methyl ether

Rubiadin-1-methyl ether 是一种口服有效的 NF-κB p65 抑制剂和自噬 (autophagy) 抑制剂,可抑制 RANKL 诱导的 p65 磷酸化与核转位,并抑制 BECN1 转录,阻遏 LC3 转化及自噬体形成,从而降低 BECN1 mRNA 和 Beclin1 蛋白水平,同时抑制破骨细胞生成、细胞增殖、巨噬细胞 M2 极化及 TGF-β1 信号通路,有效减轻肺部炎症,因而被广泛应用于骨质疏松症、肺纤维化、特发性肺纤维化以及急性肺损伤等相关疾病的研究。
产品编号: MS-F68266 纯度: 98.57% CAS No.: 7460-43-7 分子式: C16H12O4 分子量: 268.26
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Rubiadin-1-methyl ether 是一种口服有效的 NF-κB p65 抑制剂和自噬 (autophagy) 抑制剂,可抑制 RANKL 诱导的 p65 磷酸化与核转位,并抑制 BECN1 转录,阻遏 LC3 转化及自噬体形成,从而降低 BECN1 mRNA 和 Beclin1 蛋白水平,同时抑制破骨细胞生成、细胞增殖、巨噬细胞 M2 极化及 TGF-β1 信号通路,有效减轻肺部炎症,因而被广泛应用于骨质疏松症、肺纤维化、特发性肺纤维化以及急性肺损伤等相关疾病的研究。

生物实验数据

生物活性 Rubiadin-1-methyl ether is an orally effective NF-κB p65 inhibitor and autophagy inhibitor that inhibits RANKL-induced p65 phosphorylation and nuclear translocation, suppresses BECN1 transcription, blocks LC3 conversion and autophagosome formation, thereby reducing BECN1 mRNA and Beclin1 protein levels, and also inhibits osteoclastogenesis, cell proliferation, macrophage M2 polarization, and TGF-β1 signaling pathway, effectively alleviating lung inflammation, and is therefore widely used in research on related diseases such as osteoporosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, and acute lung injury.
IC50 & Target

p65

 

体外研究
(In Vitro)

Rubiadin-1-methyl ether (0.1-10 mM; 6-24 h) 在 RANKL 和 M-CSF 存在的条件下孵育 6、12 或 24 h 时,可呈浓度依赖性抑制骨髓来源破骨细胞前体细胞 (OCPs) 的增殖。
Rubiadin-1-methyl ether (0.1-10 mM; 4 d) 可呈浓度依赖性抑制 RANKL 和 M-CSF 诱导的骨髓来源破骨细胞前体细胞 (OCPs) 分化为成熟的大型破骨细胞,孵育时长为 4 天。
Rubiadin-1-methyl ether (0.1-10 mM; 4 d) 与 RANKL 和 M-CSF 共同孵育后,以浓度依赖的方式下调骨髓来源破骨细胞前体细胞 (OCPs) 中破骨细胞相关基因 (CTSK、MMP9、TRAP) 的 mRNA 表达。
Rubiadin-1-methyl ether (0.1-10 mM; 12 h) 以浓度依赖的方式抑制 RANKL 诱导的骨髓来源破骨细胞前体细胞 (OCPs) 中 LC3 的转化 (自噬的标志物)。
Rubiadin-1-methyl ether (0.1-10 mM; 12 h) 以浓度依赖的方式抑制 RANKL 诱导的骨髓来源破骨细胞前体细胞 (OCPs) 中 p65 的磷酸化。
Rubiadin-1-methyl ether (10 mM; 12 h) 可抑制 RANKL 诱导的骨髓来源破骨细胞前体细胞 (OCPs) 中 LC3 转换及 LC3 点状聚集 (自噬标志物),孵育 12 h 后该效应可被 Beclin1 激活剂 TAT-Beclin1 (MS-J03727) 逆转。
Rubiadin-1-methyl ether (10 mM; 12 h) 可逆转 RANKL 诱导的骨髓来源破骨细胞前体细胞 (OCPs) 中 p65 的核转位 (孵育 12 h 后),使胞质 p65 水平恢复至对照组的约 0.92 倍,核 p65 水平降至对照组的约 0.91 倍。
Rubiadin-1-methyl ether (10 mM; 12 h) 可降低经 RANKL 诱导的骨髓来源破骨细胞前体细胞 (OCPs) 的 BECN1 mRNA 及 Beclin1 蛋白表达,且该效应可被 Beclin1 激活剂 TAT-Beclin1 逆转。
Rubiadin-1-methyl ether (10 mM; 12 h) 可降低经 RANKL 诱导的骨髓来源破骨细胞前体细胞 (OCPs) 的 BECN1 mRNA 及 Beclin1 蛋白表达,且该效应可被 p65 过表达逆转。
Rubiadin-1-methyl ether (10 mM; 12 h) 可抑制 RANKL 诱导的骨髓来源破骨细胞前体细胞 (OCPs) 中 LC3 转化及 LC3 点状结构形成 (自噬标志物),孵育 12 h 后该效应可被 p65 过表达逆转。
Rubiadin-1-methyl ether (1-300 μM; 24 h) 在 RAW 264.7 小鼠巨噬细胞中细胞毒性较低,其 CC10 为 30 μM。
Rubiadin-1-methyl ether (3-30 μM; 24 h LPS) 在 30 μM 浓度下可逆转 LPS 诱导的 RAW 264.7 小鼠巨噬细胞凋亡率降低的现象。

Cell Differentiation Assay

Cell Line: Bone marrow-derived osteoclast precursors (OCPs)
Concentration: 0.1-10 mM
Incubation Time: 4 days
Result: Inhibited the number and size of mature osteoclasts in a concentration-dependent manner.
Reduced the number of mature osteoclasts per well to ~160 with 0.1 mM RBM, ~80 with 1 mM RBM, and ~30 with 10 mM RBM, compared to ~230 in the control group.
Reduced the number of large osteoclasts per well to ~55 with 0.1 mM RBM, ~20 with 1 mM RBM, and ~10 with 10 mM RBM, compared to ~110 in the control group.

Real Time qPCR

Cell Line: Bone marrow-derived osteoclast precursors (OCPs)
Concentration: 0.1-10 mM
Incubation Time: 4 days
Result: Reduced the mRNA expression levels of osteoclast-related genes in a concentration-dependent manner.
Reduced CTSK mRNA expression to ~0.8-fold with 0.1 mM RBM, ~0.7-fold with 1 mM RBM, and ~0.4-fold with 10 mM RBM, compared to control.
Reduced MMP9 mRNA expression to ~0.6-fold with 0.1 mM RBM, ~0.4-fold with 1 mM RBM, and ~0.3-fold with 10 mM RBM, compared to control.
Reduced TRAP mRNA expression to ~0.9-fold with 0.1 mM RBM, ~0.8-fold with 1 mM RBM, and ~0.7-fold with 10 mM RBM, compared to control.
体内研究
(In Vivo)

Rubiadin-1-methyl ether (3-30 mg/kg;口服;诱导后第 14 天单次) 在 10 mg/kg 剂量下展现出最强的抗肺纤维化功效,可显著减轻博来霉素诱导的小鼠肺部炎症、胶原沉积及 M2 巨噬细胞极化。
Rubiadin-1-methyl ether (3-30 mg/kg;口服;LPS 处理前 1 小时单次) 在 LPS 诱导的小鼠急性肺损伤模型中发挥剂量依赖性的抗炎及免疫调节作用,其中 30 mg/kg 的最高剂量对白细胞浸润、促炎介质水平及肺组织损伤的抑制作用最为显著,同时可促进 IL-10 的生成。

Animal Model: C57BL/6 (male, 10-12 weeks old, bleomycin-induced pulmonary fibrosis)
Dosage: 3 mg/kg; 10 mg/kg; 30 mg/kg
Administration: p.o.; single dose (on day 14 post-induction)
Result: Ameliorated bleomycin-induced weight loss, reduced elevated lung coefficient, attenuated lung tissue pathological damage, reduced Ashcroft fibrosis score, decreased BALF total inflammatory cells by ~47.2% (neutrophils by ~59.4%, lymphocytes by ~25.6%), downregulated lung mRNA expression of fibrosis-associated genes Fn1 by ~52.4%, Col1a1 by ~30.8%, and Acta2 by ~44.3%, reduced lung M2 macrophage (F4/80+CD206+) proportion from 28.4% to 19.8%, downregulated lung mRNA expression of M2-related genes Mrc1 by ~48.3%, Arg1 by ~46.1%, Tgfb1 by ~59%, and Il10 by ~38.7%, reduced BALF levels of TGF-β1 by ~28.7%, IL-6 by ~26.5%, IL-1β by ~55%, and TNF-α by ~51% (10 mg/kg dose).
Showed no significant reduction in total inflammatory cells, with efficacy not statistically significant compared to the bleomycin group (3 mg/kg dose).
Reduced BALF total inflammatory cells by ~49.6% (neutrophils by ~61.2%, lymphocytes by ~28.7%) with no statistical difference compared to the 10 mg/kg group, showed no additional improvement in efficacy compared to the 10 mg/kg group, with a trend toward inferior results in some measures (30 mg/kg dose).
Animal Model: Swiss mice (4-week-old male, 20-25 g, LPS-induced acute lung injury)
Dosage: 3 mg/kg; 10 mg/kg; 30 mg/kg
Administration: p.o.; single dose 1 hour pre-LPS
Result: Decreased total leukocyte count in BALF by 43.6% (10 mg/kg) and 55.3% (30 mg/kg).
Reduced neutrophil migration by 48.1% (10 mg/kg) and 68.8% (30 mg/kg).
Reduced lung fluid leakage (protein content in BALF) by 55.5% (3 mg/kg), 81.9% (10 mg/kg), and 82.9% (30 mg/kg).
Decreased NOx levels in BALF by 46.3% (3 mg/kg), 51.8% (10 mg/kg), and 60.1% (30 mg/kg).
Reduced myeloperoxidase (MPO) activity by 41.8% (3 mg/kg), 50.1% (10 mg/kg), and 54.7% (30 mg/kg).
Reduced IL-12p70 levels by 37.1% (3 mg/kg), 47.4% (10 mg/kg), and 79.5% (30 mg/kg).
Reduced IL-6 levels by 33.7% (3 mg/kg), 49% (10 mg/kg), and 79.5% (30 mg/kg).
Reduced IFN-γ levels by 64.5% (10 mg/kg) and 88.4% (30 mg/kg).
Reduced TNF-α levels by 27.7% (10 mg/kg) and 69.2% (30 mg/kg).
Reduced MCP-1 levels by 82.6% (30 mg/kg).
Increased anti-inflammatory IL-10 levels by 324.8% (10 mg/kg) and 360.5% (30 mg/kg).
Reduced lung injury histological scores by 43.4% (30 mg/kg).
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 268.26
分子式 C16H12O4
CAS No. 7460-43-7

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 125 mg/mL (465.97 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.7277 mL18.6386 mL37.2773 mL93.1932 mL
5 mM0.7455 mL3.7277 mL7.4555 mL18.6386 mL
10 mM0.3728 mL1.8639 mL3.7277 mL9.3193 mL
15 mM0.2485 mL1.2426 mL2.4852 mL6.2129 mL
20 mM0.1864 mL0.9319 mL1.8639 mL4.6597 mL
25 mM0.1491 mL0.7455 mL1.4911 mL3.7277 mL
30 mM0.1243 mL0.6213 mL1.2426 mL3.1064 mL
40 mM0.0932 mL0.4660 mL0.9319 mL2.3298 mL
50 mM0.0746 mL0.3728 mL0.7455 mL1.8639 mL
60 mM0.0621 mL0.3106 mL0.6213 mL1.5532 mL
80 mM0.0466 mL0.2330 mL0.4660 mL1.1649 mL
100 mM0.0373 mL0.1864 mL0.3728 mL0.9319 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础